Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)

Trial Profile

Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Caplacizumab (Primary) ; Caplacizumab (Primary)
  • Indications Thrombotic thrombocytopenic purpura
  • Focus Adverse reactions
  • Sponsors Ablynx
  • Most Recent Events

    • 24 Aug 2017 According to an Ablynx media release, more than 80% of eligible HERCULES patients having rolled over into this follow-up study.
    • 12 Oct 2016 Accoroding to an Ablynx media release, the first patient has rolled-over into this trial from HERCULES study.
    • 12 Oct 2016 Accoroding to an Ablynx media release, status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top